2023
DOI: 10.1016/j.radonc.2023.109637
|View full text |Cite
|
Sign up to set email alerts
|

CT-based radiomics nomogram may predict who can benefit from adaptive radiotherapy in patients with local advanced-NSCLC patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 35 publications
0
1
0
Order By: Relevance
“…As an emerging translation field, radiomics investigates the association between quantitative high-dimensional data extracted from imaging examinations and clinical data to construct a prediction model, which eventually improves evidence-based personalized medical decision-making [12,13]. In recent years, radiomics has shown great promise in predicting tumor diagnosis, molecular subtype, therapeutic effect, and survival in patients with various tumor types, including breast cancer [14,15], lung cancer [16,17], and OC [18][19][20]. A systematic review demonstrated that radiomics models have shown promising results as predictors of OS and progression-free survival (PFS) in patients with OC, but larger studies are needed to demonstrate clinical applicability [20].…”
Section: Introductionmentioning
confidence: 99%
“…As an emerging translation field, radiomics investigates the association between quantitative high-dimensional data extracted from imaging examinations and clinical data to construct a prediction model, which eventually improves evidence-based personalized medical decision-making [12,13]. In recent years, radiomics has shown great promise in predicting tumor diagnosis, molecular subtype, therapeutic effect, and survival in patients with various tumor types, including breast cancer [14,15], lung cancer [16,17], and OC [18][19][20]. A systematic review demonstrated that radiomics models have shown promising results as predictors of OS and progression-free survival (PFS) in patients with OC, but larger studies are needed to demonstrate clinical applicability [20].…”
Section: Introductionmentioning
confidence: 99%